Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H25ClFN3O6 |
Molecular Weight | 433.859 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)N2C=CC(N)=NC2=O
InChI
InChIKey=MJVKYGMNSQJLIN-KYZVSKTDSA-N
InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
Lumicitabine (formerly called ALS-8176), a first-in-class orally administered nucleoside analogue is being developed by Alios BioPharma for the treatment of respiratory syncytial virus infections. Lumicitabine converts to plasma-circulating ALS-8112, and then to the 5'-active nucleoside triphosphate (NTP) form within host cells. Extensive and rapid RSV reduction occurred after lumicitabine treatment (EC50 = 1.79 uM), with >99% viral inhibition at 2 h after loading dose. Clinical trials of Lumicitabine for the treatment of respiratory syncytial virus infection are ongoing.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02478333
Respiratory Syncytial Virus Infections: Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions. Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions. Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25667954
ALS-8176 is active in RSV replicon assay with EC50 value 0.26 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1445385-02-3
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
BNW5PQ52G1
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
Lumicitabine
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
10331
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
100000174641
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
C174641
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
DTXSID801028057
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
89658382
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
EF-23
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY | |||
|
DB14808
Created by
admin on Sat Dec 16 10:28:44 GMT 2023 , Edited by admin on Sat Dec 16 10:28:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PRODRUG)
METABOLITE ACTIVE (PRODRUG)
METABOLITE INACTIVE (PARENT)